Steven R. Messe

Steven R. Messe

Auto-generated profile, based on publicly available information

Steven R. Messe

Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.R.M.).

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
RKRobert L. Kormos
Robert L. Kormos
CAChristiaan F.J. Antonides
Christiaan F.J. Antonides
DGDaniel J. Goldstein
Daniel J. Goldstein
JCJennifer A. Cowger
Jennifer A. Cowger
RSRandall C. Starling
Randall C. Starling
FPFrancis D. Pagani
Francis D. Pagani

11 October 2016 in Neurology
Verified
Journal Article
Closed access
PDF file
SMSteven R. Messé
Steven R. Messé
PKPooja Khatri
Pooja Khatri
MRMathew J. Reeves
Mathew J. Reeves
ESEric E. Smith
Eric E. Smith
JSJeffrey L. Saver
Jeffrey L. Saver
LSLee H. Schwamm
Lee H. Schwamm
Objective: To determine patient and hospital characteristics associated with not providing IV tissue plasminogen activator (tPA) to eligible patients with acute ischemic stroke (AIS) in clinical practice. Methods: We performed a retrospective cohort study of patients with AIS arriving within 2 hours of onset to hospitals participating in Get With The Guidelines–Stroke without documented contraindications to IV tPA from April 2003 through December 2011, comparing those who received tPA to those who did not. Multivariable generalized estimating equation logistic regression modeling identified factors associated with not receiving tPA. Results: Of 61,698 eligible patients with AIS presenting within 2 hours of onset (median age 73 years, 51% female, 74% non-Hispanic white, median NIH Stroke Scale score 11, interquartile range 6–18), 15,282 (25%) were not treated with tPA within 3 hours. Failure to give tPA decreased over time from 55% in 2003 to 2005 to 18% in 2010 to 2011 (p < 0.0001). After adjustment for all covariates, including stroke severity, factors associated with failure to treat included older age, female sex, nonwhite race, diabetes mellitus, prior stroke, atrial fibrillation, prosthetic heart valve, NIH Stroke Scale score <5, arrival off-hours and not via emergency medical services, longer onset-to-arrival and door-to-CT times, earlier calendar year, and arrival at rural, nonteaching, non–stroke center hospitals located in the South or Midwest. Conclusions: Overall, about one-quarter of eligible patients with AIS presenting within 2 hours of stroke onset failed to receive tPA treatment. Thrombolysis has improved dramatically over time and is strongly associated with stroke center certification. Additionally, some groups, including older patients, milder strokes, women, and minorities, may be undertreated.

25 March 2009 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
FIfor the CHANT investigators
for the CHANT investigators
SMSteven R. Messé
Steven R. Messé
LSLauren H. Sansing
Lauren H. Sansing
BCBrett L. Cucchiara
Brett L. Cucchiara
SHSusan T. Herman
Susan T. Herman
SKScott E. Kasner
Scott E. Kasner

1 January 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
JSJae W. Song
Jae W. Song
APAthanasios Pavlou
Athanasios Pavlou
JXJiayu Xiao
Jiayu Xiao
SKScott E. Kasner
Scott E. Kasner
ZFZhaoyang Fan
Zhaoyang Fan
SMSteven R. Messé
Steven R. Messé
Background and Purpose: Intracranial atherosclerotic disease is a common cause of stroke worldwide. Intracranial vessel wall magnetic resonance imaging may be able to identify imaging biomarkers of symptomatic plaque. We performed a meta-analysis to evaluate the strength of association of imaging features of symptomatic plaque leading to downstream ischemic events. Effects on the strength of association were also assessed accounting for possible sources of bias and variability related to study design and magnetic resonance parameters. Methods: PubMed, Scopus, Web of Science, EMBASE, and Cochrane databases were searched up to October 2019. Two independent reviewers extracted data on study design, vessel wall magnetic resonance imaging techniques, and imaging end points. Per-lesion odds ratios (OR) were calculated and pooled using a bivariate random-effects model. Subgroup analyses, sensitivity analysis, and evaluation of publication bias were also performed. Results: Twenty-one articles met inclusion criteria (1750 lesions; 1542 subjects). Plaque enhancement (OR, 7.42 [95% CI, 3.35–16.43]), positive remodeling (OR, 5.60 [95% CI, 2.23–14.03]), T1 hyperintensity (OR, 2.05 [95% CI, 1.27–3.32]), and surface irregularity (OR, 4.50 [95% CI, 1.39–8.57]) were significantly associated with downstream ischemic events. T2 signal intensity was not significant ( P =0.59). Plaque enhancement was significantly associated with downstream ischemic events in all subgroup analyses and showed stronger associations when measured in retrospectively designed studies ( P =0.02), by a radiologist as a rater ( P <0.001), and on lower vessel wall magnetic resonance imaging spatial resolution sequences ( P =0.02). Conclusions: Plaque enhancement, positive remodeling, T1 hyperintensity, and surface irregularity emerged as strong imaging biomarkers of symptomatic plaque in patients with ischemic events. Plaque enhancement remained significant accounting for sources of bias and variability in both study design and instrument. Future studies evaluating plaque enhancement as a predictive marker for stroke recurrence with larger sample sizes would be valuable.

17 May 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ALAlexandra J Lansky
Alexandra J Lansky
RMRajendra Makkar
Rajendra Makkar
TNTamim Nazif
Tamim Nazif
SMSteven Messé
Steven Messé
JFJohn Forrest
John Forrest
JMJeffrey Moses
Jeffrey Moses
The REFLECT I trial investigated the safety and effectiveness of the TriGuard™ HDH (TG) cerebral embolic deflection device in patients undergoing transcatheter aortic valve replacement (TAVR). This prospective, multicentre, single-blind, 2:1 randomized (TG vs. no TG) study aimed to enrol up to 375 patients, including up to 90 roll-in patients. The primary combined safety endpoint (VARC-2 defined early safety) at 30 days was compared with a performance goal. The primary efficacy endpoint was a hierarchical composite of (i) all-cause mortality or any stroke at 30 days, (ii) National Institutes of Health Stroke Scale (NIHSS) worsening at 2–5 days or Montreal Cognitive Assessment worsening at 30 days, and (iii) total volume of cerebral ischaemic lesions detected by diffusion-weighted magnetic resonance imaging at 2–5 days. Cumulative scores were compared between treatment groups using the Finkelstein–Schoenfeld method. A total of 258 of the planned, 375 patients (68.8%) were enrolled (54 roll-in and 204 randomized). The primary safety outcome was met compared with the performance goal (21.8% vs. 35%, P < 0.0001). The primary hierarchical efficacy endpoint was not met (mean efficacy score, higher is better: −5.3 ± 99.8 TG vs. 11.8 ± 96.4 control, P = 0.31). Covert central nervous system injury was numerically lower with TG both in-hospital (46.1% vs. 60.3%, P = 0.0698) and at 5 days (61.7 vs. 76.2%, P = 0.054) compared with controls. REFLECT I demonstrated that TG cerebral protection during TAVR was safe in comparison with historical TAVR data but did not meet the predefined effectiveness endpoint compared with unprotected TAVR controls. Illustration of the TriGuard HDH and performance measures (top right panels), the primary safety endpoint at 30 days (top left panel), and 3D rendering of topographical and size distribution and total new supra-threshold cerebral ischaemic lesion volume analysis across subjects by randomization group in the intention to treat (ITT) and in the full coverage per-treatment (PT) population.

16 May 2008 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
SMSteven R. Messé
Steven R. Messé
JBJoseph E. Bavaria
Joseph E. Bavaria
MMMichael Mullen
Michael Mullen
ACAlbert T. Cheung
Albert T. Cheung
RDRebecca Davis
Rebecca Davis
MMMichael McGarvey
Michael McGarvey